FDA Approves First Drug Targeting "Undruggable" KRAS Protein in Pancreatic Cancer

The FDA approved daraxonrasib (Rasonque) on August 26, 2026 — the first targeted therapy for metastatic pancreatic cancer. In a 500-patient company-funded trial, median survival reached 13.2 months versus 6.7 for chemotherapy. The drug blocks a KRAS mutation, long deemed "undruggable," that drives over 90% of cases. Pancreatic cancer's five-year survival rate sits at 13%. The trial enrolled only previously treated patients, and its company-funded design warrants independent confirmation.